Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. (2021)
Attributed to:
Natural Killer Cells as Effectors in HIV Cure Strategies
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2352-3018(21)00103-x
PubMed Identifier: 34153264
Publication URI: http://europepmc.org/abstract/MED/34153264
Type: Journal Article/Review
Volume: 8
Parent Publication: The lancet. HIV
Issue: 8
ISSN: 2352-3018